Answers are grounded in this paper and cite their sources.
In this feasibility trial, the TAXUS slow-release stent was well tolerated and showed promise for treatment of coronary lesions, with significant reductions in angiographic and intravascular ultrasound measures of restenosis.
No takes yet. Share an insight, caveat, or question.
Grube et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: